IDEAYA Biosciences, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -8.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.18 | $-1.22 | -3.4% | Miss | |
| Q1 FY26 | $-1.07 | $-1.11 | -3.7% | Miss | |
| Q3 FY25 | $0.00 | $1.33 | not reported | Beat | |
| Q2 FY25 | $-0.85 | $-0.88 | -3.5% | Miss | |
| Q1 FY25 | $-0.75 | $-0.82 | -9.3% | Miss | |
| Q4 FY24 | $-0.67 | $-1.49 | -122.4% | Miss | |
| Q3 FY24 | $-0.67 | $-0.60 | +10.4% | Beat | |
| Q2 FY24 | $-0.55 | $-0.68 | -23.6% | Miss | |
| Q1 FY24 | $-0.53 | $-0.53 | +0.0% | Beat | |
| Q4 FY23 | $-0.49 | $-0.52 | -6.1% | Miss | |
| Q3 FY23 | $-0.47 | $-0.46 | +2.1% | Beat | |
| Q2 FY23 | $-0.53 | $-0.50 | +5.7% | Beat |
Back to IDYA overview · IDYA holders · IDYA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.